Cogitars
Cogitars specializes in providing advanced statistical support for innovative development in the pharmaceutical, medical device, and diagnostics industries, with a strong focus on Bayesian methodologies. They aim to transform uncertainty into opportunity by offering services such as Bayesian statistics for dose escalation and optimization (including FDA's Project Optimus), Bayesian decision rules for Phase 2/3 studies, comprehensive statistical support for clinical trials with an emphasis on the Estimand framework, and visual trial monitoring & reporting using Python/R and AI technologies. Their unique selling proposition lies in offering specialized, A-team level biostatistical support, contrasting with the perceived limitations of traditional CRO models, and utilizing a broader range of advanced statistical tools for quicker turnaround and flexible engagement. Their Bayesian methods improve correct dose identification rates to 70-75% compared to the traditional 3+3 design's 30%.
Cogitars
Cogitars specializes in providing advanced statistical support for innovative development in the pharmaceutical, medical device, and diagnostics industries, with a strong focus on Bayesian methodologies. They aim to transform uncertainty into opportunity by offering services such as Bayesian statistics for dose escalation and optimization (including FDA's Project Optimus), Bayesian decision rules for Phase 2/3 studies, comprehensive statistical support for clinical trials with an emphasis on the Estimand framework, and visual trial monitoring & reporting using Python/R and AI technologies. Their unique selling proposition lies in offering specialized, A-team level biostatistical support, contrasting with the perceived limitations of traditional CRO models, and utilizing a broader range of advanced statistical tools for quicker turnaround and flexible engagement. Their Bayesian methods improve correct dose identification rates to 70-75% compared to the traditional 3+3 design's 30%.